IRIS
PRONZATO, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.018
Totale 2.018
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 2.018
Totale 2.018
Salva come PNG Salva come JPEG
Città #
Genova 1.189
Rapallo 360
Genoa 345
Vado Ligure 114
Bordighera 10
Totale 2.018
Salva come PNG Salva come JPEG
Nome #
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial 123
Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients 113
Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: Results of an observational study 112
New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients 111
Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial 110
Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives 95
Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis 91
Estrone sulphate, FSH, and testosterone levels in two male breast cancer patients treated with aromatase inhibitors 90
Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors 85
Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group 84
Medical approaches to preservation of fertility in female cancer patients 81
Stevens-johnson syndrome after treatment with bendamustine 78
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study 75
Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients 71
Assessing the Impact of the COVID-19 Outbreak on the Attitudes and Practice of Italian Oncologists Toward Breast Cancer Care and Related Research Activities 70
Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival A Randomized Clinical Trial 65
Use in current clinical practice of 70-gene signature in early breast cancer 64
Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients. 63
Economic Impact of Inter-Regional Health Mobility In The Oldest European Administrative Region: A Starting Point For Changing Organizational Model? 61
Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: Extending endocrine sensitivity 56
Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. 52
null 44
A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients 43
Current state of the art on the diagnosis and the role of target therapy for treatment of ROS1-rearranged non-small cell lung cancer: a narrative review 38
Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: a systematic review and meta-analysis 36
Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives 30
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 29
Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature 28
Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center 25
Experience with a nurse-driven genetic counseling pathway of Italian women with uninformative BRCA test result 20
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis 15
Patterns of care at the end of life: a retrospective study of Italian patients with advanced breast cancer 12
Corrigendum to "Gene expression profiling in breast cancer: A clinical perspective" [The Breast 22 (2013) 109-120 [doi:10.1016/j.breast.2013.01.016.]] 10
The Impact of the Introduction of the Breast Unit Model in a Northwestern Italian Region 9
Thymidine labeling index analysis in early breast cancer patients randomized to receive perioperative chemotherapy 7
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study 7
Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: A randomised study 6
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study 5
Totale 2.114
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.338
article - articoli 9.338
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.676
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020531 0 0 0 39 44 79 101 59 56 86 52 15
2020/2021207 12 21 11 36 9 11 12 24 10 30 9 22
2021/2022252 12 12 14 28 4 32 5 53 22 31 10 29
2022/2023417 27 45 5 27 75 63 5 46 65 11 45 3
2023/2024296 10 31 17 44 21 26 39 12 10 23 11 52
2024/2025137 41 61 27 8 0 0 0 0 0 0 0 0
Totale 2.114